IP Library › Granted Patent US 10,927,417
Granted Patent B2
US 10,927,417 · App. 15/644,721 · Granted Feb 23, 2021

Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

Inventors: Jennifer E. Beane-Ebel (Rio Rancho, NM); Anna Tassinari (Boston, MA); Avrum Spira (Newton, MA); Marc E. Lenburg (Berkeley, CA)
Assignee: Trustees of Boston University
C12Q1/6886C12Q2600/112C12Q2600/118C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,927,417
App. No.
15/644,721
Granted
Feb 23, 2021
Kind
B2
Abstract

Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.

Claims (6)

1. A method of processing a sample from a subject suspected of having a premalignant bronchial lesion comprising the steps of: (a) providing a biological sample from the mouth or nose of the subject or from a brushing of the bronchi walls of the subject; and (b) measuring the expression of five or more genes in the sample by northern-blot hybridization, a ribonuclease protection assay, or a reverse transcriptase polymerase chain reaction (RT-PCR) method, wherein the five or more genes comprise ZXDC, ESR1, MYH3, RBM19, and TIMM23.

2. The method of claim 1 , wherein the five or more genes further comprise at least one gene selected from AFG3L1P, TTC31, CSAD, SZT2, C15orf63, PPP1R3E, CRIPAK, FAM219A, NXF1, NISCH, ECHDC2, SRRM2, EZH1, PION, KIAA0907, SESN2, SUGP2, RBM33, TTLL3, SRCAP, ZFYVE26, IKBKB, ANKRD11, MLLT11, AVIL, ZNF445, SRGAP2, SH3BP2, DDX39B, ZNF473, DDX54, FAM65C, DDX17, CCDCl93, BAZ2A, TJAP1, MCM3AP-AS1, PNN, ZNF160, LY6G5B, SGSH, KCNC3, MAU2, C5orf45, CAPRIN2, SAFB2, MED12, PPP1R12B, ZNF767, TP73-AS1, ACIN1, SIN3B, MOV10, STX16, MYO9B, NPIPL3, ATAT1, HNRNPH1, RUSC2, SLC22A5, TMEM198B, EWSR1, SPEN, MDC1, BCL9L, TMEM131, NFRKB, ASXL1, PHKA2, TRIM66, GTPBP1, SLC12A9, PXK, ELMOD3, TNRC6A, C1orf63, DNAH1, MYBBP1A, SFSWAP, CNNM3, SEPT7P2, FKBP15, WDR37, TSC1, JMJD7-PLA2G4B, MKNK1, ZNF142, LENG8, GGA1, GIT2, SF1, MED15, ZNF37BP, CTC1, KANSL3, PPRC1, PAPD7, INTS3, DCAF5, SRSF5, SLC2A11, TAZ, RALGPS1, DICER1-AS1, C14orf159, LRP5L, JRK, PASK, KCTD7, KIAA0182, ZBTB40, GON4L, ZNF337, POGZ, C12orf51, ALS2CL, GIGYF1, ARAP3, SLC25A45, PDE7A, IL6R, FAM178A, CATSPER2, C1orf132, TBC1D2B, CDAN1, ZNF646, TRPV1, ATXN2L, ZNF335, VPS39, AGK, DGCR8, PHF12, GRIPAP1, ATXN2, CAD, UBE2G2, KDM2A, C22orf29, PHF21A, FMNL2, CUL9, CAMTA2, TPT1-AS1, CDCl42SE1, CHD8, AP1G2, PLXNA3, ZNF251, PNISR, FAM53C, GGT7, STAT6, BRD4, CREBBP, RG9MTD3, MYO18A, NAPB, SEMA6A, NUMA1, TRMU, CEP164, DOT1L, FLNB-AS1, ZNF692, HEATR8, PRR14, ZNF580, RPS8, EAPP, RPS7P11, UBE2N, RPL12P4, DPCD, NPM1, RPLP2, MRPL22, GTF2H5, HBXIP, C2orf76, NDUFS5, ATP6V1D, RPL8, COX6A1, CCDCl56, RPL13AP5, ATP6V1E1, RPL39P3, ZNF32, DAD1, RPL32, RPL37A, PEX2, CD9, RPS2, PPIAP22, CDC123, JTB, CONY, UCHL3, UQCRFS1, RPL38, RPS6, UQCRQ, GOLPH3L, OST4, NME5, C6orf108, MRPL54, RPL10AP2, COX4I1, COX5A, CCDCl72, COX14, COPS4, EI24, UQCRH, NDUFA1, RPL29, RPL4, OCIAD2, SEPW1, ATP5I, SNRPD2, MOSPD1, NDUFC2, MRPL36, RPL10A, MCTS1, FAM3D, C19orf43, TPI1, TMEM230, MRPL23, NDUFA8, COX5B, HIGD2A, TSEN34, C15orf48, GTF2A2, APOO, C17orf61, ENSG00000167524, ENSG00000229180, ENSG00000182873, ENSG00000247484, ENSG00000257479, ENSG00000205047, ENSG00000255847, ENSG00000245149, ENSG00000253200, ENSG00000215769, ENSG00000225828, ENSG00000224660, ENSG00000205885, ENSG00000235027, ENSG00000205890, ENSG00000249093, ENSG00000215039, ENSG00000258461, ENSG00000234290, ENSG00000238105, ENSG00000230124, ENSG00000184551, ENSG00000228544, ENSG00000258727, ENSG00000218418, ENSG00000247743, ENSG00000235297, ENSG00000186198, ENSG00000185641, ENSG00000236801, ENSG00000244398, and ENSG00000232856.

3. The method of claim 1 , wherein the five or more genes comprise cDNA.

4. The method of claim 1 , wherein the expression of five or more genes in the sample is measured by an RT-PCR method.

5. The method of claim 1 , wherein the biological sample is obtained from the mouth of the subject.

6. The method of claim 1 , wherein the subject has a positive result in an imaging study of a premalignant bronchial lesion.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2017
From: BEANE-EBEL, JENNIFER E.; TASSINARI, ANNA; SPIRA, AVRUM; LENBURG, MARC E.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 044466/0645 →
Continuity (2)
Provisional Application 62360218 · Jul 8, 2016
Related Publication 20180010197A1 · Jan 11, 2018
Cited By (5)
US 12,297,503 US 12,297,505 US 12,305,238 US 12,534,763 US 12,577,620